Your browser doesn't support javascript.
loading
Identification of an Individualized Prognostic Biomarker for Serous Ovarian Cancer: A Qualitative Model.
Luo, Fengyuan; Li, Na; Zhang, Qi; Ma, Liyuan; Li, Xinqiao; Hu, Tao; Zhong, Haijian; Li, Hongdong; Hong, Guini.
Afiliação
  • Luo F; School of Medical Information Engineering, Gannan Medical University, Ganzhou 341000, China.
  • Li N; School of Medical Information Engineering, Gannan Medical University, Ganzhou 341000, China.
  • Zhang Q; Affiliated Hospital of Jiangxi, University of Chinese Medicine, Nanchang 330006, China.
  • Ma L; School of Medical Information Engineering, Gannan Medical University, Ganzhou 341000, China.
  • Li X; School of Medical Information Engineering, Gannan Medical University, Ganzhou 341000, China.
  • Hu T; School of Medical Information Engineering, Gannan Medical University, Ganzhou 341000, China.
  • Zhong H; School of Medical Information Engineering, Gannan Medical University, Ganzhou 341000, China.
  • Li H; School of Medical Information Engineering, Gannan Medical University, Ganzhou 341000, China.
  • Hong G; School of Medical Information Engineering, Gannan Medical University, Ganzhou 341000, China.
Diagnostics (Basel) ; 12(12)2022 Dec 12.
Article em En | MEDLINE | ID: mdl-36553135
ABSTRACT
Serous ovarian cancer is the most common type of ovarian epithelial cancer and usually has a poor prognosis. The objective of this study was to construct an individualized prognostic model for predicting overall survival in serous ovarian cancer. Based on the relative expression orderings (Ea > Eb/Ea ≤ Eb) of gene pairs closely associated with serous ovarian prognosis, we tried constructing a potential individualized qualitative biomarker by the greedy algorithm and evaluated the performance in independent validation datasets. We constructed a prognostic biomarker consisting of 20 gene pairs (SOV-P20). The overall survival between high- and low-risk groups stratified by SOV-P20 was statistically significantly different in the training and independent validation datasets from other platforms (p < 0.05, Wilcoxon test). The average area under the curve (AUC) values of the training and three validation datasets were 0.756, 0.590, 0.630, and 0.680, respectively. The distribution of most immune cells between high- and low-risk groups was quite different (p < 0.001, Wilcoxon test). The low-risk patients tended to show significantly better tumor response to chemotherapy than the high-risk patients (p < 0.05, Fisher's exact test). SOV-P20 achieved the highest mean index of concordance (C-index) (0.624) compared with the other seven existing prognostic signatures (ranging from 0.511 to 0.619). SOV-P20 is a promising prognostic biomarker for serous ovarian cancer, which will be applicable for clinical predictive risk assessment.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prognostic_studies / Qualitative_research Idioma: En Revista: Diagnostics (Basel) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prognostic_studies / Qualitative_research Idioma: En Revista: Diagnostics (Basel) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China